3 Promising Penny Stocks With Market Caps Larger Than $200M

Over the last 7 days, the U.S. market has remained flat, but it is up 17% over the past year with earnings expected to grow by 17% annually in the coming years. In light of these conditions, investors may seek stocks that balance affordability with growth potential, making penny stocks an intriguing option. Although often associated with smaller or newer companies, penny stocks can offer significant value when backed by strong financials and a clear growth trajectory.

We're going to check out a few of the best picks from our screener tool.

ProKidney (PROK)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: ProKidney Corp. is a clinical-stage biotechnology company focused on developing cell therapies for chronic kidney diseases in the United States, with a market cap of approximately $559.30 million.

Operations: ProKidney generates revenue from its biotechnology startup segment, amounting to $0.82 million.

Market Cap: $559.3M

ProKidney, a clinical-stage biotechnology firm, remains pre-revenue with sales under US$1 million. Despite being unprofitable and not expected to achieve profitability in the next three years, the company is debt-free and has short-term assets of US$189.8 million covering both its short- and long-term liabilities. The management team is experienced with an average tenure of 2.8 years, while shareholders have not faced significant dilution recently. ProKidney's inclusion in multiple Russell indices highlights market recognition despite recent insider selling and a negative return on equity due to ongoing losses.

• Click here to discover the nuances of ProKidney with our detailed analytical financial health report.
• Examine ProKidney's earnings growth report to understand how analysts expect it to perform.

Rocket Pharmaceuticals (RCKT)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Rocket Pharmaceuticals, Inc. is a late-stage biotechnology company specializing in the development, manufacturing, and sale of genetic therapies for rare and severe diseases in the United States, with a market cap of approximately $409.46 million.

Operations: Rocket Pharmaceuticals does not currently report any revenue segments.

Market Cap: $409.46M

Rocket Pharmaceuticals, a late-stage biotechnology company, is pre-revenue with no significant income streams yet. Recent earnings reports showed a turnaround with net income of US$123.21 million for Q2 2026, compared to a loss the previous year. Despite being unprofitable and not expected to achieve profitability soon, Rocket has sufficient cash runway exceeding three years and remains debt-free. The company's promising clinical updates on RP-A501 for Danon disease have been well-received, though its management team is relatively new with an average tenure of 1.2 years. Recent index changes reflect mixed market sentiment toward the stock's potential growth trajectory.

• Take a closer look at Rocket Pharmaceuticals' potential here in our financial health report.
• Review our growth performance report to gain insights into Rocket Pharmaceuticals' future.

MacroGenics (MGNX)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: MacroGenics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, manufacturing, and commercializing antibody-based cancer therapeutics in the United States with a market cap of $257.35 million.

Operations: The company generates revenue of $175.14 million from its segment focused on developing innovative antibody-based therapeutics for cancer treatment.

Market Cap: $257.35M

MacroGenics, Inc. has shown significant revenue growth, reporting US$32.83 million in Q2 2026 compared to US$6.87 million a year ago, and a net income of US$19.52 million after previous losses. The company benefits from strategic collaborations, such as with Gilead Sciences, which recently exercised an option triggering a US$10 million payment to MacroGenics. Additionally, the FDA's approval of TZIELD for type 1 diabetes treatment has resulted in a US$24.5 million milestone payment from Sanofi. Despite being unprofitable with declining earnings forecasts, MacroGenics is debt-free and maintains sufficient cash runway for over a year.

• Get an in-depth perspective on MacroGenics' performance by reading our balance sheet health report here.
• Learn about MacroGenics' future growth trajectory here.

Turning Ideas Into Actions

• Gain an insight into the universe of 316 US Penny Stocks by clicking here.
• Contemplating Other Strategies? Trump has pledged to "unleash" American oil and gas and these 23 US stocks have developments that are poised to benefit.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com